Good Morning Readers,
 

We are excited to unveil our newest pick, Cardiol Therapeutics Inc. (Nasdaq: CRDL), a trailblazing clinical-stage life sciences company focused on heart disease treatment.
 

Cardiol Therapeutics Inc. (Nasdaq: CRDL) has been making headlines with its recent breakthroughs, sparking considerable interest among analysts. With price targets of $8.00 and $9.00, there’s a potential upside of over 195% from current levels. This under-the-radar company is on the cusp of drawing major attention from Wall Street.

 (1)(2)(3)(4)

(2)

Here’s why you should take notice:
 

🔔 Pending Breakthrough News: The company has hinted at major news dropping in Q2, which could ignite significant breakout buzz.(1)(2)(3)(4) 

⛓️ Strong Partners: They partner with world-renowned researchers and clinicians at leading international centers of excellence. These collaborations equip them with the best insights and knowledge, driving their mission to heal hearts with groundbreaking science. 

(5)

🎯 Bullish Technical Indicators: Cardiol is showing strong technical signals, with multiple short, medium, and long-term indicators turning bullish. Barchart’s “Trend Seeker” is also triggered, pointing to a potential upward trend.(1)(2)(3)(4)
 

💼 Strategic Progress: Cardiol is nearing the completion of key strategic transactions, including the acquisition of a prominent manufacturer, enhancing their financial and operational strength.(1)(2)(3)(4)
 

🧨 Potential Catalysts:

• Topline results for the MAvERIC-Pilot Phase II study are expected soon.

• The FDA has granted Orphan Drug Designation for Cardiol’s lead drug candidate, CardiolRx™, further validating its therapeutic potential.(1)(2)(3)(4)
 

With its focus on innovative anti-inflammatory and anti-fibrotic therapies for heart disease, Cardiol Therapeutics Inc. (Nasdaq: CRDL) is poised for significant growth. Their lead drug candidate, CardiolRx™, is in clinical development and has shown promising results in treating conditions like pericarditis, myocarditis, and heart failure. (1)(2)(3)(4)
 

We continue to work tirelessly to identify the next big opportunity, and all of our indicators point toward Cardiol Therapeutics Inc. (Nasdaq: CRDL).This company is just starting to gain momentum, so make sure it’s on your radar now!
 

Don’t miss out on this game-changer. Stay tuned for more updates! 📻
 

To your continued success,

Max Masters

Co-founder, Market Tips Newsletter

Sources:
1. https://finance.yahoo.com/quote/CRDL/
2. https://www.tipranks.com/stocks/crdl/forecast
3. https://finance.yahoo.com/news/cardiol-therapeutics-announces-phase-ii-112700140.html
4. https://www.cardiolrx.com/wp-content/uploads/2024/06/Cardiol-Therapeutics-%E2%80%93-Corporate-Presentation_June-2024.pdf
5. https://www.cardiolrx.com/

Data is provided from third-party sources and Market Tips is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized fin.ancial advice, are not finan.cial advisors, and our opinions are not suitable for all in.vest.ors. Please review our full disc.laim.er here. 

Pursuant to an agreement between Momentum Media LLC and TD Media LLC, Momentum Media LLC has been hired for a period beginning on 06/11/2024 and ending on 06/12/2024 to publicly disseminate information about (CRDL:US) via digital communications. To date we have been paid sixteen thousand dollars USD. We own zero shares of (CRDL:US).